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Key PointsWe report a high rate of ID and ASD in this series of DS patients aged from 2‐ to 7‐years‐oldParental reports for cognitive assessment such as CDI are effective in DSPatients with DS present a specific ASD profile with relative preservation of social skills

1. INTRODUCTION {#epi412281-sec-0006}
===============

Dravet syndrome (DS) is a rare childhood epilepsy characterized by pharmacoresistant seizures that begin usually in the first year of life. DS is a developmental early onset epileptic encephalopathy with moderate to severe intellectual disability (ID), motor impairment, and behavioral/psychiatric disturbances.[1](#epi412281-bib-0001){ref-type="ref"}, [2](#epi412281-bib-0002){ref-type="ref"}, [3](#epi412281-bib-0003){ref-type="ref"}

DS has a typical developmental trajectory with almost normal development in the first year of life. A cognitive slowing usually appears between the second and the third years of life and stabilizes around the age of 6 years.[1](#epi412281-bib-0001){ref-type="ref"}, [2](#epi412281-bib-0002){ref-type="ref"}, [4](#epi412281-bib-0004){ref-type="ref"} Fifty‐eight percent to 100% of patients show ID extending from mild to profound.[4](#epi412281-bib-0004){ref-type="ref"}, [5](#epi412281-bib-0005){ref-type="ref"}, [6](#epi412281-bib-0006){ref-type="ref"}, [7](#epi412281-bib-0007){ref-type="ref"}, [8](#epi412281-bib-0008){ref-type="ref"}

Neuropsychological phenotypes of patients with DS are heterogeneous, but there is evidence that visual functions are impaired early and show a persistent delay over time.[1](#epi412281-bib-0001){ref-type="ref"}, [3](#epi412281-bib-0003){ref-type="ref"}, [9](#epi412281-bib-0009){ref-type="ref"} Nonverbal Wechsler scores are usually worse than verbal skills.[10](#epi412281-bib-0010){ref-type="ref"}, [11](#epi412281-bib-0011){ref-type="ref"}, [12](#epi412281-bib-0012){ref-type="ref"} Motor disabilities, particularly fine motor skills and gait disturbances, are also frequently reported.[4](#epi412281-bib-0004){ref-type="ref"}, [7](#epi412281-bib-0007){ref-type="ref"}, [13](#epi412281-bib-0013){ref-type="ref"}, [14](#epi412281-bib-0014){ref-type="ref"}

Most of DS patients develop language but with pronounced dysfunctions such as oral motor impairment, dysarthria, speech planning difficulties, and expressive language deficits.[3](#epi412281-bib-0003){ref-type="ref"}, [4](#epi412281-bib-0004){ref-type="ref"}, [7](#epi412281-bib-0007){ref-type="ref"}, [10](#epi412281-bib-0010){ref-type="ref"}, [11](#epi412281-bib-0011){ref-type="ref"}, [13](#epi412281-bib-0013){ref-type="ref"}, [15](#epi412281-bib-0015){ref-type="ref"} Complex cognitive ability deficits, such as categorization and executive disorders, have also been reported.[4](#epi412281-bib-0004){ref-type="ref"}, [12](#epi412281-bib-0012){ref-type="ref"}, [13](#epi412281-bib-0013){ref-type="ref"} The causes of these cognitive dysfunctions are still unknown, but underlying genetic dysfunction seems to play a key role.[2](#epi412281-bib-0002){ref-type="ref"}, [3](#epi412281-bib-0003){ref-type="ref"}

Autism spectrum disorder (ASD) features have been reported in patients with DS but were defined as « autistic traits » without using standardized tools. Depending on the type of assessment (Table [1](#epi412281-tbl-0001){ref-type="table"}), rates of "autistic traits" vary from 8.3% to 61.5%.[4](#epi412281-bib-0004){ref-type="ref"}, [6](#epi412281-bib-0006){ref-type="ref"}, [16](#epi412281-bib-0016){ref-type="ref"}, [17](#epi412281-bib-0017){ref-type="ref"}, [18](#epi412281-bib-0018){ref-type="ref"}, [19](#epi412281-bib-0019){ref-type="ref"}, [20](#epi412281-bib-0020){ref-type="ref"} Most studies have reported lack of verbal communication, with 10%‐79% of patients showing social problems, such as poor peer relationships, being withdrawn, lack of emotional reciprocity, social rules problems, or excessive familiarity.[6](#epi412281-bib-0006){ref-type="ref"}, [18](#epi412281-bib-0018){ref-type="ref"}, [19](#epi412281-bib-0019){ref-type="ref"}, [21](#epi412281-bib-0021){ref-type="ref"}, [22](#epi412281-bib-0022){ref-type="ref"}, [23](#epi412281-bib-0023){ref-type="ref"} Restricted and unusual interests, like obsessions, perseverations, or self‐stimulations, are reported in 24%‐69%.[6](#epi412281-bib-0006){ref-type="ref"}, [18](#epi412281-bib-0018){ref-type="ref"}, [19](#epi412281-bib-0019){ref-type="ref"}, [24](#epi412281-bib-0024){ref-type="ref"} Neophobia,[6](#epi412281-bib-0006){ref-type="ref"}, [19](#epi412281-bib-0019){ref-type="ref"} adherence to routines and sensory particularities, are less described.[18](#epi412281-bib-0018){ref-type="ref"}, [25](#epi412281-bib-0025){ref-type="ref"}

###### 

Description of "autistic features" in patients with Dravet syndrome (DS) in the literature

                                                                                   No. patients   Age (y)          Assessment instruments                  \% ASD   Autistic traits %           Social problems %                 Communication/language disorders                         No play with toys %   Restricted interests RI, Repetitive behavior %                          Hyperactivity, attention problems %   Other
  -------------------------------------------------------------------------------- -------------- ---------------- --------------------------------------- -------- --------------------------- --------------------------------- -------------------------------------------------------- --------------------- ----------------------------------------------------------------------- ------------------------------------- --------------------------
  Nabbout et al. (2009)[3](#epi412281-bib-0003){ref-type="ref"}                    28             11 (4‐24)        Clinical evaluation                     NA       46.4                        NA                                No language 53.6, few words 32.1, short sentences 14.3   NA                    NA                                                                      22.2                                  NA
  Ragona et al. (2011)[2](#epi412281-bib-0002){ref-type="ref"}                     26             5‐19             Clinical evaluation                     NA       15.4                        NA                                NA                                                       NA                    NA                                                                      83.3; 69.2                            NA
  Dravet et al. (2011)[21](#epi412281-bib-0021){ref-type="ref"}                    NA             NA               Clinical evaluation                     NA       NA                          No play with peers                Language delay                                           Yes                   NA                                                                      Attention                             NA
  Ceulemans et al. (2011)[16](#epi412281-bib-0016){ref-type="ref"}                 60/24          NA               Vineland                                8.3      NA                          NA                                NA                                                       NA                    NA                                                                      Yes                                   NA
  Genton et al. (2011)[17](#epi412281-bib-0017){ref-type="ref"}                    24             20‐50            Clinical evaluation                     25       NA                          NA                                Language impairment 100                                  NA                    NA                                                                      NA                                    NA
  Chieffo et al. (2011)[4](#epi412281-bib-0004){ref-type="ref"}                    12             Survey 2‐6 y     Griffith\'s dev. scale                  8.3      NA                          NA                                NA                                                       NA                    NA                                                                      NA                                    NA
  Brunklaus et al. (2011)[22](#epi412281-bib-0022){ref-type="ref"}                 163            7.2              SDQ, PedsQL                             NA       NA                          Peer relationship 75              NA                                                       NA                    NA                                                                      Attention 66                          Conduct problem 33
  Skluzacek et al. (2011) (2005 cohort)[18](#epi412281-bib-0018){ref-type="ref"}   65             7.7 (\<1‐36)     Clinical evaluation                     18       40                          Withdrawn 18                      Echolalia 18, no language 48, language delay 68          14                    Self‐stimulation 26, perseveration 35, obsessions 24                    20                                    Excessive familiarity 47
  Skluzacek (2011) (2009 cohort)[18](#epi412281-bib-0018){ref-type="ref"}          86             7.7 (\<1‐36)     Clinical evaluation                     21       33                          10                                Echolalia 24, no language 28, language delay 83          30                    Self‐stimulation 20, perseveration 52, obsessions 40                    34                                    Excessive familiarity 56
  Li et al. (2011)[6](#epi412281-bib-0006){ref-type="ref"}                         37             9.3 (2.8‐12.3)   DSM‐IV‐TR, ICD‐10, ABC, CARS            24.3     97.3 at least one feature   Emotional reciprocity 27          Speech delay 91.9: language regression 10.8              NA                    Adherence to routine 32.4, restricted interests 55                      NA                                    54.1 short temper
  Villeneuve et al. (2013)[23](#epi412281-bib-0023){ref-type="ref"}                21             6‐20             Vineland                                NA       100 at least one feature    Gaze, friendships, social rules   91% verbal IQ \< 60                                      NA                    Unusual + restricted interests                                          Opposition/provocation                Excessive familiarity
  Berkvens et al. (2015)[19](#epi412281-bib-0019){ref-type="ref"}                  13             34.7 (18‐60)     AVZ‐R, SGZ, TVZ                         61.5     NA                          69.2                              84.6                                                     69.2                  Stereotyped use, adherence to routine 46.1; restricted interests 69.2   None                                  Self‐mutilation
  Rosander et al. (2015)[20](#epi412281-bib-0020){ref-type="ref"}                  42             7 (1‐17)         Play observations, parental interview   36       16                          7                                 NA                                                       NA                    NA                                                                      NA                                    NA
  Villas et al. (2017)[24](#epi412281-bib-0024){ref-type="ref"}                    220            8 (0.9‐32)       Parental survey                         NA       67                          53                                Language delay 84                                        49                    68                                                                      50                                    Excessive familiarity 57

ABC, Autism Behavior Checklist; AVZ‐R, Pervasive Developmental Disorder in Mental Retardation scale‐Revised; CARS, Childhood Autism Rating Scale; DSM‐IV‐TR, Diagnostic and Statistical Manual of Mental Disorders Revised, Fourth Edition; ICD‐10, International Classification of Diseases, Tenth Revision; NA, not available; PedsQL, Pediatric Quality of Life Inventory; SDQ, Strength and Difficulties Questionnaire; SGZ, Maladaptive behavior scale for individuals with ID; TVZ, Temperament scale for individuals with ID.
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Only one study assessed ASD in children with DS using standardized tools: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV‐TR) and the International Classification of Diseases, Tenth Revision (ICD‐10) criteria, the Childhood Autism Rating Scale (CARS) diagnosis tool, and the Autism Behavior Checklist (ABC),[6](#epi412281-bib-0006){ref-type="ref"} but without any gold standard diagnosis tool (Autism Diagnostic Interview‐Revised \[ADI‐R\] or Autism Diagnostic Observation Schedule, Second Edition \[ADOS‐2\]). Yet, it is known that the combination of an expert clinician evaluation with ADI‐R and ADOS‐2 is the most efficient approach to performing an accurate diagnosis of ASD.[26](#epi412281-bib-0026){ref-type="ref"} Finally, characterization of developmental and behavioral phenotypes in patients with DS remains challenging in clinical practice due to the child\'s fatigability, time‐consuming evaluations, and the need for expert teams and tools adapted to severe cognitive and behavioral disorders that are lacking to date.

This study aimed to (1) delineate ASD and ID profiles in young children with DS using adapted gold standard tools, and (2) test a battery of cognitive assessment, with parental questionnaires and cognitive tests, in order to identify a rapid, reproducible, and sensitive tool to evaluate the cognitive abilities in children with DS.

2. MATERIALS AND METHODS {#epi412281-sec-0007}
========================

2.1. Patients {#epi412281-sec-0008}
-------------

We enrolled 35 consecutive patients with DS followed at our center, age 24 months to 7 years, from 2013 to 2017. We excluded patients with a developmental age (DA) \<18 months. This study had the approval of our institution\'s ethics committee.

2.2. Cognitive and adaptive assessment {#epi412281-sec-0009}
--------------------------------------

The cognitive assessment was performed by 2 neuropsychologists (DL, ZB) and included a standardized observational examination (Psychoeducational Profile, Third Edition; PEP‐3)[27](#epi412281-bib-0027){ref-type="ref"} using both cognitive and behavioral subscales for all patients. In addition, patients' parents filled out a questionnaire (Child Development Inventory \[CDI\][28](#epi412281-bib-0028){ref-type="ref"}; French version, IDE[29](#epi412281-bib-0029){ref-type="ref"}) and underwent a parent interview (Vineland Adaptive Behavior Scales, Second Edition \[VABS‐II\],[30](#epi412281-bib-0030){ref-type="ref"} French Adaptation ECPA).

For PEP‐3, results are reported in developmental levels based on percentiles (Adapted Level ‐percentile rank, \>89; Mild Level percentile rank, 75‐89; Moderate Level percentile rank, 25‐74; and Severe Level percentile rank, \<25). In addition, we calculated developmental quotients (DQs) from the DA to enable comparison between patients' scores. Then we calculated mean DQ for cognitive scales for each patient. DQs were also calculated for CDI scales. For VABS‐II, standardized scores are reported. Children older than 6 years were excluded from motor assessment, as there is a ceiling score at 6 years for this item. DQ categorization is the following: normal, DQ 115‐85; high risk of delay, DQ 84‐70; and very high risk of delay, DQ \<70.

2.3. Autism spectrum disorder diagnosis and profiles {#epi412281-sec-0010}
----------------------------------------------------

Autism spectrum disorder (or ASD) diagnosis was performed combining (1) a systematic psychiatric examination by the expert (LO) to assess clinically the ASD symptoms and Diagnostical and Statistical Manual of Mental Disorders, Fifth Revision (DSM‐5) criteria[31](#epi412281-bib-0031){ref-type="ref"} with 2 diagnosis gold standard tools: a parental interview (ADI‐R)[32](#epi412281-bib-0032){ref-type="ref"} and an observational tool (ADOS‐2).[33](#epi412281-bib-0033){ref-type="ref"}

The DSM‐5 [31](#epi412281-bib-0031){ref-type="ref"} defines the following ASD criteria: deficits in all 3 of the Social Communication (SC) criteria (deficits in socioemotional reciprocity; in nonverbal communicative behavior; and in developing, maintaining, and understanding relationship), and at least 2 of the 4 criteria listed under Restricted and Repetitive Behaviors (RRBs: stereotyped or repetitive movements or use of objects; insistence on sameness; restricted or fixed interests; hyper or hyporeactivity to sensory inputs).

The Autism Diagnostic Interview‐Revised (or ADI‐R) is a semi‐structural parental autism diagnosis questionnaire that assesses 3 domains: Communication, Social Interaction, and RRBs. An algorithm of subscore combination defines thresholds for ASD for each domain.

The Autism Diagnostic Observation Schedule (or ADOS‐2) is composed of 4 modules that are adapted to age and verbal communication level. The test consists of a set of situations or games that are videotaped to observe the child in situations requiring play and social behavior. Five domains are evaluated: Communication, Social Interaction, Play, Repetitive Behaviors, and Other Behaviors (hyperactivity, anxiety, and so on). In addition, ADOS‐2 provides a severity score. Videos were coded by 2 trained specialists (LO, DB). ADOS‐2 was proposed when (1) patients showed clinical autistic symptoms at psychiatric examination and/or (2) at least one socialization or communication ADI‐R domain reached the threshold for ASD.

Children who had DSM‐5 criteria for ASD and pathologic scores in all ADI‐R and ADOS‐2 domains, were diagnosed with ASD. Children who had DSM‐5 criteria for Social Communication Disorder (SCD) and pathologic scores in ADI‐R and ADOS‐2 domains, but not for RRBs, were classified as SCD. Children without abnormalities or with abnormalities in only some domains of DSM‐5 were rated "no ASD diagnosis." In the case of discrepancies between DSM‐5 criteria and ADI‐R and ADOS‐2 thresholds, the final diagnosis was provided by the expert.[26](#epi412281-bib-0026){ref-type="ref"}

2.4. Statistical analysis {#epi412281-sec-0011}
-------------------------

JMP v.12 software (SAS Institute Inc.) was used for all statistical procedures.

Cohort descriptive statistics were done for age, gender, and for scores for the questionnaires and scales performed. The effect of age on the test and questionnaire scores or results was assessed using analysis of variance (ANOVA) by the slope test (leverage) of the linear fit. Contingency analyses were made by the chi‐square test for likelihood. Most of the numerical data were expressed as scores showing no normal distribution; therefore nonparametric tests were used for the analyses comparing only scores. Using multivariate analysis, the correlations between the different evaluated scores were determined and tested on the Spearman\'s rank‐order correlation coefficient Rho.

Group comparisons were achieved by Student\'s *t* test (one tailed) or by one‐way ANOVA with subsequent Wilcoxon test, or by logistic regression depending on the role of the categorical and numerical variables.

For all analyses, the differences were considered statistically significant if the *P*‐value was below 0.05. The significances were further coded as follows: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.

3. RESULTS {#epi412281-sec-0012}
==========

We enrolled 35 children with DS diagnosis. Five were excluded, having DA of\<18 months. Thirty patients were included: 18 girls (60%) and 12 boys (40%). They were ages 26 to 91 months (mean age 63.2 months; median age 64.5 with quartiles of 46.8 and 78.0 months). Patients' demographic and clinical data are reported in Table [2](#epi412281-tbl-0002){ref-type="table"}. All patients had PEP‐3 scale evaluation; 28 (93%) had psychiatric examination. Twenty‐six parents (86%) filled out the CDI questionnaire and 28 (93%) the VABS‐II.

###### 

Genetic, seizure, and neurodevelopmental assessment data

  No.   Age at inclusion (mo)   Gender   Mutation *SCN1A*                                                                Exon/intron   De novo/heredity   Age at onset of seizure (mo)   Trigger     Seizures semiology                      Status epilepticus at onset   Age at treatment introduction (mo)   Treatment            Autism   Delay (CDI)   Delay (PEP‐3)
  ----- ----------------------- -------- ------------------------------------------------------------------------------- ------------- ------------------ ------------------------------ ----------- --------------------------------------- ----------------------------- ------------------------------------ -------------------- -------- ------------- ---------------
  1     84                      M        Negative                                                                        NA            NA                 8                              Fever       F                                       N                             8                                    VPA, STP, CLB        No       ++            ++
  2     33                      M        c1165C3T                                                                        Exon 8        NA                 5                              Fever/Vac   GTC                                     Y                             6                                    VPA, CLB, TPM, STP   No       NA            ++
  3     87                      M        c.580G\>A/p.Asp194Asn                                                           Exon 4        De novo            9                              Fever       GTC                                     N                             NA                                   VPA, CLB, STP        No       ++            ++
  4     64                      F        c.4219C\>T/p.Arg1407X                                                           Exon 21       NA                 9                              Fever       TC right                                Y                             12                                   VPA, TPM             ASD      ++            ++
  5     65                      M        p.lys868Asn C.2604G\>C                                                          Exon 15       Mother             6                              Fever       GTC                                     N                             8                                    VPA, CLB, TPM        No/SCD   ++            \+
  6     91                      M        c.473+1G\>A                                                                     Intron 3      De novo            4                              Fever       GTC                                     Y                             4                                    VPA                  No       ++            ++
  7     50                      M        c.2360T\>G/p.Met787Arg                                                          Exon 13       De novo            9                              Fever/Vac   F                                       Y                             13                                   VPA, CLB, STP        ASD      \+            \+
  8     45                      F        c.2836C\>T/p.Arg946Cys                                                          Exon 15       De novo            6                              Fever       GTC                                     N                             8                                    VPA, CLB, STP        No       ++            ++
  9     71                      F        Negative                                                                        NA            NA                 6                              Fever       Atonic, GTC                             N                             7                                    TPM, VPA, CLB, CZP   ASD      ++            ++
  10    35                      F        c.4476+1_4476+5del                                                              Intron 23     De novo            6                              Fever       GTC                                     N                             6                                    VPA, CLB, STP        No       ++            ++
  11    62                      M        Negative                                                                        NA            NA                 13                             Fever       GTC                                     N                             20                                   VPA, TPM, STP        No       ++            ++
  12    58                      F        Negative                                                                        NA            NA                 10                             Fever       F, GTC, pattern sensitivity myoclonia   N                             16                                   VPA, LEV, CLB        NA       ++            \+
  13    35                      F        c.568T\>C/p.Trp190Arg                                                           Exon 4        De novo            7                              Fever       F                                       Y                             10                                   VPA, CLB             No       \+            −
  14    26                      M        c.5734C\>T p.(Arg1912\*)                                                        Exon 26       De novo            2                              Vac         GTC                                     N                             4                                    VPA                  No       ++            \+
  15    77                      F        c.1378C\>T/p.GIn460                                                             Exon 10       De novo            10                             No          GTC                                     N                             10                                   VPA                  No       ++            ++
  16    64                      F        Negative                                                                        NA            NA                 5                              No          C                                       Y                             13                                   VPA, CLB, STP        NO/SCD   ++            ++
  17    57                      M        c.2951T\>G/p.Leu984Arg exon 16; (c.4339‐34_4339‐30delTggta intron 22 variant)   Exon 16       De novo            6                              Fever       GC                                      N                             6                                    VPA, CLB, STP        ASD      NA            ++
  18    90                      M        c.5040delC/p.Met1681CysfsX1714                                                  Exon 26       De novo            4                              Fever       Hemicorporal                            N                             10                                   VPA, CLB, STP        ASD      ++            ++
  19    57                      F        NA                                                                              NA            NA                 3                              No          GTC                                     Y                             3.5                                  Br, VPA, CLB, STP    No       NA            ++
  20    91                      M        c.2792G\>A/p.Arg931His                                                          Exon 15       De novo            5                              Fever       GTC                                     Y                             5                                    VPA, CLB, STP        ASD      ++            ++
  21    78                      F        c.5209A\>T (p.Lys1737\*)                                                        Exon 26       De novo            7                              Fever       GTC                                     Y                             8                                    VPA, STP, CLB        ASD      ++            ++
  22    46                      M        c.1129C\>T/p.Arg377X                                                                          NA                 6                              Fever       GTC                                     Y                             8                                    VPA, CLB             NA       −             \+
  23    40                      F        c.3213del (p.Asp1072llefs\*8)                                                   Exon 16       De novo            7                              Fever       Right hemiclonic                        Y                             8                                    LEV, VPA, CLB, TPM   No       \+            \+
  24    78                      F        c.4757delG/p.Gly1586GlufsX5                                                     Exon 25       NA                 3                              Fever       GTC                                     N                             6                                    VPA, CLB, STP        ASD      ++            ++
  25    47                      F        c.1849A\>T/p.Arg617X                                                            Exon 11       De novo            6                              No          F                                       N                             10                                   VPA, STP, CLB        No       \+            ++
  26    70                      F        c.455C\>T/p.Pro1519Ser                                                          Exon 24       Mother             9                              No          GTC                                     Y                             10                                   VPA, CLB             ASD      ++            ++
  27    77                      F        c.235G\>T.Asp 79Tyr                                                             Exon 1        Mosaicism mother   8                              Fever       GTC                                     N                             NA                                   CLB, VPA, STP        ASD      NA            ++
  28    69                      M        c.974A\>G/p.Tyr325Cys                                                           NA            NA                 7                              Fever       GTC                                     Y                             7                                    VPA                  No       ++            ++
  29    67                      F        Negative                                                                        NA            NA                 7                              Fever       T                                       NA                            NA                                   VPA, STP, CLB        ASD      ++            ++
  30    81                      F        c.602+1G\>A i                                                                   Intron 4      De novo            9                              Fever       GTC                                     Y                             12                                   VPA, STP, CLB        No       ++            ++

ASD, Autism Spectrum Disorder; BR, potassium bromide; C, clonic seizures; CLB, clobazam; CZP, clonazepam; FS, focal seizures; GC, generalized clonic seizures; GTC, generalized tonic‐clonic seizures; LEV, levetiracetam; M, myoclonic; NA, not available; SCD, Social Communication Disorder; STP, stiripentol; TC, tonic‐clonic seizures; TPM, topiramate; Vac, vaccination; VPA, sodium valproate; (−), no risk of delay; (+) = high level risk of delay, DQ \<85; (++) very high risk of delay, QD \<70 (categorization of delay were obtained with mean PEP‐3 cognitive DQ).
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3.1. Cognitive assessment {#epi412281-sec-0013}
-------------------------

### 3.1.1. Psychoeducational Profile, Third Edition {#epi412281-sec-0014}

The analysis of PEP‐3 subscales showed pathologic developmental levels (mild, moderate, or severe levels) in the majority of patients. The Affective Expression (AE) scale was the least affected measure, with only 13 of 30 patients (43%) showing pathologic levels (Figure [1](#epi412281-fig-0001){ref-type="fig"}). Patients obtained worse scores with a moderate or severe developmental level---percentile rank \<75 for Fine Motor (FM, 27/30 patients, 90%), Cognitive Verbal/Preverbal (CVPV, 24/30, 80%), Gross Motor (GM, 24/30), Visual Motor Imitation (VMI, 21/30, 70%), and Expressive Language (EL, 19/30, 63%) subscales (Figure [1](#epi412281-fig-0001){ref-type="fig"}).

![Upper graph---proportion of patients for each developmental level of PEP‐3 scale according to the subscales. CVPV, Cognitive Verbal/Preverbal; EL, Expressive Language; RL, Receptive Language; FM, Fine Motor; GM, Gross Motor; VMI, Visual Motor Imitation; AE, Affective Expression; SR, Social Reciprocity; CMB, Characteristic Motor Behaviors; CVB, Characteristic Verbal Behaviors. Lower graph: Proportion of patients for each developmental level of the CDI scale according to the subscales. Soc, Social; SH, Self Help; GM, Gross Motor; FM, Fine Motor; EL, Expressive Language; LC, Language Comprehension; Let, Letters; Num, Numbers; GS, General Scale](EPI4-4-40-g001){#epi412281-fig-0001}

DQs were calculated for the cognitive scales: EL (mean \[m\] = 48; 18‐80), GM (m = 52; 29‐89), FM (m = 56; 36‐92), Receptive Language (RL, m = 57; 16‐90), VMI (m = 57; 32‐114), CVPV (m = 60; 26‐97).

Considering mean DQ for cognitive scales for all 30 patients, one patient had no risk of delay (3%), 6 patients had a high risk of delay (20%), and 23 had a very high risk of delay (77%).

### 3.1.2. Child Development Inventory {#epi412281-sec-0015}

Twenty‐six parents filled out the CDI. Twenty‐one patients (81%) presented a very high‐level risk of delay for the general scale (DQ \< 70), 4 of 26 (15%) a high level risk (70 ≤ DQ \< 85), and one patient (4%) was in the normal range (Figure [1](#epi412281-fig-0001){ref-type="fig"}). Patients with high risk or in the normal range were in the youngest group of patients (\<50 months).

### 3.1.3. VABS‐II {#epi412281-sec-0016}

Twenty‐eight parents underwent the VABS‐II interview. For the global score (adaptive behavior), standard scores ranged from 56 to 105 (mean = 75). Mean scores for each domain ranged from 71 (Motor Skills; 56‐90) to 79 (Daily Living Skills; 59‐115). Ten children were older than 6 years of age and were excluded from motor assessment (36%).

### 3.1.4. Coherence of parental questionnaires/PEP‐3 scale {#epi412281-sec-0017}

The coherence between the CDI questionnaire and the PEP‐3 was evaluated comparing the common domains for PEP‐3 and CDI scales (DA). EL (*ρ* = 0.76, \*\*\**P* \< 0.001), RL (*ρ* = 0.55, \*\**P* = 0.002), FM (*ρ* = 0.59, \*\**P* = 0.001), and GM (*ρ* = 0.7271, \*\*\**P* = 0.001) were significantly correlated. Furthermore, the CDI general score was significantly correlated with all of the PEP‐3 cognitive variables: CVPV (*ρ* = 0.6367, \*\*\**P* = 0.001), EL (*ρ* = 0.7515, \*\*\**P* \< 0.001), RL (*ρ* = 0.6272, \*\*\**P* = 0.001), FM (*ρ* = 0.5618, \*\**P* = 0.002), GM (*ρ* = 0.6322, \*\*\**P* = 0.001), and VMI (*ρ* = 0.5431, \*\**P* = 0.003).

The chi‐square test showed no difference between PEP‐3 and CDI categorization among very high risk of delay categorization for receptive communication (*P* = 0.49), expressive communication (*P* = 0.75), and gross motor (*P* = 0.03). The categorization for fine motor showed differences (*P* = 0.010), with a higher number of very high risk of delay for PEP‐3 compared to the CDI parental questionnaire.

The VABS‐II global adaptive behavior score was significantly correlated with PEP‐3 DQ for GM (*ρ* = 0.6033, \*\*\**P* \< 0.001), FM (*ρ* = −0.5211, \*\**P* = 0.004), VMI (*ρ* = −0.5108, \*\**P* = 0.005), EL (*ρ* = −0.4837, \*\**P* = 0.009), RL (*ρ* = −0.3848, \**P* = 0.04), and Characteristic Verbal Behavior scores (CVB, *ρ* = −0.3902, \**P* = 0.04), but not with CVPV (*ρ* = −0.337, *P* = 0.07), AE (*ρ* = −0.3154, *P* = 0.10), Social Reciprocity (SR, *ρ* = −0.1768; *P* = 0.36), and Characteristic Motor Behavior (CMB, *ρ* = −0.2409; *P* = 0.21) scores.

### 3.1.5. Link between cognitive and adaptive levels with patient\'s age {#epi412281-sec-0018}

Age of patient at assessment was not linked to the PEP‐3 DA for RL, VMI, and FM, whereas it was with CVPV (*ρ* = 0.4109; \**P* \< 0.05), EL (*ρ* = 0.4154; \**P* \< 0.05), and GM (*ρ* = 0.3694; \**P* \< 0.05).

Nevertheless, for the RL and CDI General Scale, from 50 months of life, 2 distinct populations emerged (Figure [2](#epi412281-fig-0002){ref-type="fig"}): a first group with increasing DA over chronological age, and the second showing a stagnation of DA through chronologic age.

![Nonparametric density plot of bivariate analyses of the variables "PEP‐3 Receptive Language" and "CDI General Scale" with respect to Age (M = months)](EPI4-4-40-g002){#epi412281-fig-0002}

Child Development Inventory (or CDI) scores were not correlated with age, except for Letters (*ρ* = 0.4692, \**P* = 0.01), and Numbers subscales (*ρ* = 0.4869, \*\**P* = 0.01).

VABS‐II Socialization (\**P* = 0.01), Daily Living Skills (\**P* = 0.01), Motor Skills (\*\**P* = 0.001), and Adaptive Behavior (\**P* = 0.02) domains were negatively correlated with age, whereas the Communication domain did not reach statistical significance (*P* = 0.10).

3.2. Autism spectrum disorder assessment {#epi412281-sec-0019}
----------------------------------------

### 3.2.1. Descriptive data {#epi412281-sec-0020}

Twenty‐eight patients had a psychiatric examination (Figure [3](#epi412281-fig-0003){ref-type="fig"}). Twenty‐six had ADI‐R. The 2 patients who did not have ADI‐R were younger than 3 years and had no ASD symptoms according to the DSM‐5. Fourteen patients reached the threshold for at least one ADI‐R domain (54%). Fifteen had ADOS‐2, 13 after the ADI‐R and 2 after detecting ASD isolated clinical features on psychiatric examination. Figure [3](#epi412281-fig-0003){ref-type="fig"} shows the different ASD assessment scales and the results obtained in this cohort.

![Flow chart for diagnosis of autism spectrum disorder](EPI4-4-40-g003){#epi412281-fig-0003}

According to the DSM‐5 classification and ADI‐R and ADOS‐2 (Figure [3](#epi412281-fig-0003){ref-type="fig"}), 11 patients showed ASD (39%) and 2 had an SCD diagnosis (7%). The 15 remaining patients (54%) had neither ASD nor SCD.

### 3.2.2. Comparison of ASD/non‐ASD children for ADI‐R {#epi412281-sec-0021}

To confirm the clinical phenotype of DS children, we compared means of ADI‐R subscores between those who fulfill the criteria for ASD and those who did not (Figure [4](#epi412281-fig-0004){ref-type="fig"}). In both groups, the social interaction profile of DS children is heterogeneous ("star" profile in Figure [4](#epi412281-fig-0004){ref-type="fig"}). However, DS patients with ASD showed a significantly higher impairment of direct gaze (\*\*\**P* = 0.004), range of facial expressions (\**P* = 0.04), imaginative group play (\**P* = 0.01), interest in children (\*\**P* = 0.001), response to approaches (\**P* = 0.04), showing attention (\*\**P* \< 0.001), share enjoyment (\**P* = 0.02), use of others' body (\**P* = 0.03), and appropriate social response (\**P* = 0.01; Figure [4](#epi412281-fig-0004){ref-type="fig"}). In the nonverbal language domain, DS patients with ASD showed significantly more difficulties in imaginative play (\*\**P* = 0.008), pointing (\**P* = 0.04), and conventional gestures (\**P* = 0.02). In the RRB domain, DS patients with ASD showed significant differences in unusual preoccupations (\**P* = 0.02), compulsions (\**P* = 0.03), repetitive use of objects (\**P* = 0.02), and unusual sensory interests (\**P* = 0.04). However, unusual sensory interests have been found in 47% of the patients with no ASD (7/15).

![Comparison of ADI‐R 3 subscores between Dravet syndrome (DS) children with autism spectrum disorder (ASD; in red) and DS children without ASD (in blue)](EPI4-4-40-g004){#epi412281-fig-0004}

### 3.2.3. Correlation between ADI‐R domains and ADOS‐2 severity scores, and according to age at assessment {#epi412281-sec-0022}

None of ADI‐R domains and ADOS‐2 severity score were correlated, but there was a trend between the Reciprocal Social Interaction ADI‐R subscore and the ADOS‐2 severity score (*P* = 0.07). The age at assessment was correlated positively with the Reciprocal Social Interaction domain of ADI‐R (\**P* = 0.01), and Communication domain (\**P* = 0.03), but not with RRBs. However, the ADOS‐2 severity score was not linked to age.

### 3.2.4. Correlation between ASD and cognitive assessment {#epi412281-sec-0023}

We found significant negative correlations between ADOS‐2 severity score and each PEP‐3 score (DQ; bivariate analysis) for RL (*R* ^2^ = 0.233396, \*\*\**P* \< 0.001), CVPV (*R* ^2^ = 0.190286, \*\**P* = 0.001), EL (*R* ^2^ = 0.062743, \*\**P* = 0.005), FM (*R* ^2^ = 0.163454, \**P* = 0.01), GM (*R* ^2^ = 0.085568, \**P* = 0.01), and VMI (*R* ^2^ = 0.055015, \**P* = 0.04).

When we divided the group of DS patients (ASD vs \[non ASD + SCD\]), there were significant differences in the PEP‐3 cognitive DQs between the 2 groups (Student\'s unilateral *t* test) in RL (\*\*\**P* \< 0.001), VMI (\*\**P* = 0.001), CVPV (\*\**P* = 0.002), GM (\*\**P* = 0.002), FM (\**P* = 0.02), and EL (\**P* = 0.04), with higher DQ for no ASD + SCD patients. Both groups showed differences for all behavioral PEP‐3 developmental levels: SR (\*\*\**P* \< 0.001), CVB (\*\**P* = 0.006), AE (\*\**P* = 0.01), and CMB (\**P* = 0.01; Wilcoxon test).

Logistic regression for ASD diagnosis with PEP‐3 scores (DQ) showed significant effects for RL (\*\**P* = 0.004), CVPV (\**P* = 0.01), GM (\**P* = 0.02), and VMI (\**P* = 0.02); and with behavioral PEP‐3 scales: SR (\*\**P* = 0.007), CVB (\**P* = 0.01), AE (\**P* = 0.01), and CMB (\**P* = 0.02), but failed to reach significance for EL, FM, and CMB.

For patients older than 50 months of age, 2 groups emerged (ASD/no ASD; Figure [2](#epi412281-fig-0002){ref-type="fig"}). The two groups showed a difference at Student\'s unilateral *t* test for PEP‐3 scores (DQ) in RL (\*\*\**P* \< 0.001) and CVPV (\*\**P* = 0.007). The 2 groups showed differences for all behavioral PEP‐3 developmental levels for SR (\*\**P* = 0.005), CVB (\**P* = 0.02\*), CMB (\**P* = 0.04), and AE (\**P* = 0.04; Wilcoxon test).

Logistic regression for ASD diagnosis explained by cognitive PEP‐3 scores (DQ) in patients older than 50 months showed significant effects for RL (\**P* = 0.01) and CVPV (\**P* = 0.03), and for 3 behavioral PEP‐3 developmental levels: SR (\**P* = 0.01), CVB, (\**P* = 0.03), and AE (\**P* = 0.04).

### 3.2.5. Links between ASD and adaptive behavior (VABS‐II) {#epi412281-sec-0024}

The logistic regression for ASD diagnosis explained by VABS‐II showed a significant effect for Socialization (\**P* = 0.01), Motor Skills (\**P* = 0.01), and Adaptive Behavior (\**P* = 0.048), but no significant effect on Communication (*P* = 0.09) and Daily Living Skills (*P* = 0.07).

3.3. Correlations between medical variables and neuropsychiatric features {#epi412281-sec-0025}
-------------------------------------------------------------------------

### 3.3.1. Medical variables and cognitive features {#epi412281-sec-0026}

We explored a possible link between the presence of the *SCN1A* mutation, the age at onset of seizure (in months), and status epilepticus at onset, with cognitive delay (cognitive delay: DQ \<70 based on mean DQ for cognitive scales) and PEP‐3 cognitive subscales (PEP‐3 DQs).

Only the age at onset of seizures showed a trend for statistical significance for Expressive Language DQ (simple linear regression, ANOVA *F* test: *P* = 0.055) and RL DQ (*P* = 0.056): patients with higher DQs had later onset. All other *P*‐values for PEP‐3 DQ and cognitive delay were above 0.14.

### 3.3.2. Medical variables and ASD features {#epi412281-sec-0027}

We also explored the possible link between the medical and genetic variables with ASD variables (ASD diagnosis, ADOS‐2 severity score). No significant *P*‐values were found (all *P* \> 0.22).

4. DISCUSSION {#epi412281-sec-0028}
=============

We report a high prevalence of ASD in our cohort: 11 (39%) if we exclude SCDs according to DSM‐5 and 13 (46%) ASD when we include SCDs, according to the ICD‐10. This rate is relevant considering the use of 2 gold standard scales but might be underestimated, as we excluded the children presenting a DA less than 18 months.

The occurrence of ASD in DS is controversial. Guzzettta[25](#epi412281-bib-0025){ref-type="ref"} does not mention autistic traits. Ceulemans et al[16](#epi412281-bib-0016){ref-type="ref"} and Villeneuve et al[23](#epi412281-bib-0023){ref-type="ref"} concluded that children with DS do not present ASD, as the socialization scale of the VABS‐II is almost always better when compared to the overall results of the scale. This assumption often leads to ASD being underdiagnosed and prevents patients from benefitting from structured and adapted care. In addition, we found a significant correlation between the VABS‐II socialization subscale and ASD, suggesting that the preservation of the VABS\'s socialization score reported[23](#epi412281-bib-0023){ref-type="ref"} might apply to patients with DS as a group but not for the subgroup of DS patients with ASD.

Two series reported the prevalence of ASD in patients with DS at 23.9%[6](#epi412281-bib-0006){ref-type="ref"} in children and 61.5%[19](#epi412281-bib-0019){ref-type="ref"} in adults. The underestimation of ASD in the pediatric series could be related to a relative preservation of the communicative skills.[16](#epi412281-bib-0016){ref-type="ref"}, [23](#epi412281-bib-0023){ref-type="ref"} Adult patients were clinically diagnosed with autism, but had preserved social skills, with a discrepancy between *regular* autistic features, and the inappropriate familiarity with strangers.[19](#epi412281-bib-0019){ref-type="ref"} The relative preservation of social smiling in our series and the fact that 17 of 30 patients had adapted Affective Expression on PEP‐3, show that children with DS and ASD show more pro‐socials features than expected for a typical case of autism and explain again the underestimated prevalence of ASD in previous reports. Although communicative skills are partly preserved, patients present qualitatively unadapted social behaviors. A similar phenotype has been described in patients with ASD due to de novo genetic etiologies compared to patients with ASD and no genetic abnormalities.[34](#epi412281-bib-0034){ref-type="ref"}

In our series, 23 of 30 patients (77%) presented ID. We used the PEP‐3 scale, since it is designed especially for "hard to assess" children. Classical intelligence scales (Wechsler scales) are challenging and poorly adapted for patients with ASD, and with ID in general. On PEP‐3, cognitive deficits were higher than behavioral disturbances, showing a genuine cognitive delay before the age of 7 years. Expressive language, gross motor, and fine motor scales showed the lowest DQ mean scores. Visuomotor and fine motor development were not correlated with age at assessment, showing a stagnation of the acquisitions and slow improvement of the performances, as described previously.[9](#epi412281-bib-0009){ref-type="ref"}, [12](#epi412281-bib-0012){ref-type="ref"} Although gait impairment is reported[35](#epi412281-bib-0035){ref-type="ref"} we showed an improvement of gross motor scales over age.[3](#epi412281-bib-0003){ref-type="ref"}, [7](#epi412281-bib-0007){ref-type="ref"} This emphasizes the need for adapted rehabilitation.

Language was delayed, with a discrepancy between receptive and expressive domains; the latter was more affected. This sensorimotor integration deficit might be explained by the dorsal stream impairment hypothesis also proposed for the visuomotor skill impairment in DS.[36](#epi412281-bib-0036){ref-type="ref"}, [37](#epi412281-bib-0037){ref-type="ref"} However, expressive skills are better in older patients, suggesting a possible dynamic of acquisition in this domain, whereas RL skills did not show this age‐related pattern.

Verbal/Preverbal cognitive scales, as well as prescholar acquisition with letter and number acquisitions, showed better scores in older patients. This suggests a nonprogressive disorder with a potential for improvement and learning, as reported in a smaller previous longitudinal study.[3](#epi412281-bib-0003){ref-type="ref"}

Parents' questionnaires (IDE) in our cohort showed high consistency with psychologist\'s assessment for cognitive development. We found a high consistency between parents' assessment of cognitive skills (IDE) and the domains of the PEP‐3, except for fine motor evaluation. This validates the usefulness of these questionnaires and allows us to propose them as promising tools to evaluate children with DS when the PEP‐3 tool is challenging to use with patients with certain characteristics (excessive behavior disorder, child fatigability, or interruption with seizures, and so on). These questionnaires can be considered as an easy primary evaluation tool that may be extended to use in other early onset epilepsies syndromes with ID.

The correlation between ASD and ID in DS has been proposed previously[6](#epi412281-bib-0006){ref-type="ref"}, [19](#epi412281-bib-0019){ref-type="ref"} and was found to be significant also in our cohort. DS patients with ASD presented greater cognitive deterioration than patients without ASD, and ASD severity was linked with ID severity. RL deficit seemed the most significantly correlated with ASD. This particular cognitive feature is to be emphasized, as previously more attention had been given to visuospatial[4](#epi412281-bib-0004){ref-type="ref"}, [9](#epi412281-bib-0009){ref-type="ref"}, [10](#epi412281-bib-0010){ref-type="ref"}, [11](#epi412281-bib-0011){ref-type="ref"}, [12](#epi412281-bib-0012){ref-type="ref"}, [25](#epi412281-bib-0025){ref-type="ref"}and expressive language impairments.

We encountered 2 distinct populations of children with DS after the age of 50 months (Figure [2](#epi412281-fig-0002){ref-type="fig"}): one with cognitive impairment and ASD, and the other with less cognitive impairment and no ASD. The absence of ASD patients in the youngest group (maybe because children children under 18 months of DA had not been included in the study) could also partly explain this divide. It is challenging to define the onset of first ASD symptoms, due to the confounding factor of ID. In our cohort, age at assessment was linked with reciprocal social interaction at ADI‐R. It is possible that problems with social interactions increase with age, due to a specific phenotype in social cognition, or because of a consequence of instrumental problems, especially executive function (EF). This age of 50 months, corresponding to the beginning of the preschool years, is a key period for the development of EF and attention.[38](#epi412281-bib-0038){ref-type="ref"} We could hypothesize that cognitive and adaptive tasks are too demanding regarding EF for children with DS. This is consistent with the dysexecutive syndrome hypothesis.[23](#epi412281-bib-0023){ref-type="ref"} These 2 groups have to be confirmed with a larger sample and a longitudinal study.

The links between ID and ASD are not fully understood. ID and ASD are suspected to be partly linked to the genetic underlying disease and not exclusively related to epilepsy.[3](#epi412281-bib-0003){ref-type="ref"} Nevertheless, we did not find any significant link between the presence of ASD and ID, and age at onset, status epilepticus at onset, and the presence of *SCN1A* mutation. The nearly significant trend with age at onset and language features is relevant with the early maturation of language brain networks. A genetic common pathway for seizures, ID, and ASD is reported in many genetic conditions[39](#epi412281-bib-0039){ref-type="ref"} and might be partly relevant for DS where the impairment of the sodium channel *SCN1A* function can explain not only the seizures but also the ASD and the ID.[40](#epi412281-bib-0040){ref-type="ref"} This hypothesis has to be confirmed in a larger sample.

The high rate and the atypical phenotype of ASD in DS found in this series have major clinical implications. This finding supports the necessity to use standardized tools such as ADI‐R and ADOS‐2 for ASD diagnosis. This diagnosis should allow personalized and targeted interventions on specific difficulties in order to decrease the severity of associated ASD comorbidity and its possible impact on cognitive development.

4.1. Study limitations {#epi412281-sec-0029}
----------------------

This study had some limitations. The number of patients in both groups before and after 50 months was not similar and did not allow to confirm a significant difference between the two groups and a cut‐off age at 50 months. We did not assess the number of seizures, as we had incomplete data. We faced other limitations due to the instruments and the scores we used. Because we used 3 ADOS‐2 modules, we could not perform a comparison on ADOS‐2 items but used comparison scores to assess severity scores. The motor scores of the VABS‐II showed a ceiling effect at 6 years. Finally, patients were followed in the same tertiary center, and this might have generated a patient group that was more severely affected.

5. CONCLUSION {#epi412281-sec-0030}
=============

The present study indicates a high prevalence of ID and a high rate of ASD, showing a specific profile (relative preservation of social skills) in this cohort of DS. The use of parental questionnaire can provide a good assessment of cognitive profile and could help overcome the difficulty of addressing cognitive scales. This cognitive evaluation is of major importance as patients with severe ID are more at risk for ASD. A global cognitive survey is recommended early, addressing language skills, and particularly receptive skills, which are linked to autistic disorders. Specific rehabilitation programs (motor and logopedic) for patients with ASD, focusing specifically on RL and alternative communication methods, should be introduced and implemented.

The diagnosis and the phenotyping of ASD is another critical step in evaluating patients with DS. Insights into core processes of ASD and links between ASD and ID are needed, as we know that early interventions with infants and with their parents[41](#epi412281-bib-0041){ref-type="ref"} improve outcomes of autistic features. The role of the sodium channel disorder on the cognitive outcome and on ASD is highly suspected[40](#epi412281-bib-0040){ref-type="ref"}, [42](#epi412281-bib-0042){ref-type="ref"} but we should also question the impact of nondiagnosed ASD on patients' cognitive development and outcome. This methodology should be extended to other early onset developmental epileptic encephalopathies in order to better delineate the phenotype of these diseases beyond seizures but also to better define the endpoints to propose to evaluate future therapies.
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